SPPI · Spectrum Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.62M | - | - | - | - | - | - | - | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.42M | - | $13.34M | $16.01M | $4.19M | - | $20.85M | $29.11M | $19.37M | - |
| SG&A | $14.00M | - | $8.26M | $9.38M | $9.87M | - | $12.24M | $14.96M | $14.31M | - |
| Total Operating Expenses | $20.48M | - | $21.60M | $25.39M | $14.06M | - | $33.09M | $44.07M | $33.69M | - |
| D&A | $45.0K | - | - | - | $73.0K | - | - | $0 | $65.0K | - |
| Operating Income | ($4.87M) | - | ($21.60M) | ($25.39M) | ($14.06M) | - | ($33.09M) | ($44.07M) | ($33.69M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $16.0K | $13.0K | $16.0K | - | $0 | $16.0K | ($7.0K) | - |
| Net Income | ($5.01M) | - | ($21.93M) | ($29.05M) | ($15.44M) | - | ($33.08M) | ($50.13M) | ($35.70M) | - |
| EPS - Basic | ($0.02) | - | ($0.12) | ($0.17) | ($0.25) | - | ($0.21) | ($0.32) | - | - |
| EPS - Diluted | ($0.02) | - | ($0.12) | ($0.17) | ($0.09) | - | ($0.37) | ($0.32) | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.37M | $40.37M | $56.26M | $25.51M | $78.68M | $88.54M | $107.44M | $114.57M | $69.52M | $46.01M |
| Accounts Receivable | $32.76M | $13.00M | - | - | - | $0 | $0 | $0 | $64.0K | $67.0K |
| Inventory | $12.86M | $9.23M | $0 | - | - | - | - | - | - | - |
| Accounts Payable | $22.79M | $30.55M | $35.01M | $26.15M | $25.30M | $33.41M | $40.91M | $41.86M | $33.58M | $34.38M |
| Current Assets | $105.38M | $101.01M | $112.98M | $73.58M | $93.18M | $103.95M | $140.00M | $165.71M | $169.21M | $186.65M |
| Total Assets | $107.67M | $103.34M | $118.93M | $79.43M | $100.05M | $111.55M | $147.80M | $175.04M | $179.01M | $196.80M |
| Current Liabilities | $38.88M | $42.69M | $49.62M | $41.04M | $39.21M | $53.23M | $57.27M | $56.70M | $47.38M | $53.15M |
| Long-term Debt | $28.84M | $28.67M | $0 | - | - | - | - | - | - | - |
| Total Liabilities | $80.87M | $75.45M | $83.08M | $45.99M | $44.80M | $63.99M | $68.34M | $66.46M | $56.57M | $62.55M |
| Stockholders' Equity | $26.80M | $27.89M | $35.85M | $33.44M | $55.26M | $47.55M | $79.46M | $108.59M | $122.44M | $134.24M |
| Retained Earnings | ($1.12B) | ($1.12B) | ($1.11B) | ($1.09B) | ($1.06B) | ($1.04B) | ($1.00B) | ($971.12M) | ($920.99M) | ($885.29M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($21.44M) | - | - | - | ($30.30M) | - | - | - | ($34.49M) | - |
| Investing Cash Flow | $31.33M | - | - | - | $428.0K | - | - | - | $36.64M | - |
| Financing Cash Flow | $2.11M | - | - | - | $20.00M | - | - | - | $21.36M | - |
| CapEx | $108.0K | - | - | - | $39.0K | - | - | - | $73.0K | - |
| Free Cash Flow | ($21.55M) | - | - | - | ($30.34M) | - | - | - | ($34.56M) | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -31.2% | - | - | - | - | - | - | - | - | - |
| EBITDA margin | -30.9% | - | - | - | - | - | - | - | - | - |
| Net margin | -32.1% | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | -138.0% | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 4.30 | - | - | - | 1.96 | - | - | - | 0.97 | - |
| R&D / Revenue | 34.7% | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 89.6% | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -4.7% | - | -18.4% | -36.6% | -15.4% | - | -22.4% | -28.6% | -19.9% | - |
| Return on equity | -18.7% | - | -61.2% | -86.9% | -27.9% | - | -41.6% | -46.2% | -29.2% | - |
| Return on invested capital | -6.9% | - | -47.6% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.71 | 2.37 | 2.28 | 1.79 | 2.38 | 1.95 | 2.44 | 2.92 | 3.57 | 3.51 |
| Quick ratio | 2.38 | 2.15 | 2.28 | 1.79 | 2.38 | 1.95 | 2.44 | 2.92 | 3.57 | 3.51 |
| Cash ratio | 1.35 | 0.95 | 1.13 | 0.62 | 2.01 | 1.66 | 1.88 | 2.02 | 1.47 | 0.87 |
| Leverage | ||||||||||
| Debt / Equity | 1.08 | 1.03 | 0.00 | - | - | - | - | - | - | - |
| Debt / Assets | 0.27 | 0.28 | 0.00 | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 4.02 | 3.71 | 3.32 | 2.38 | 1.81 | 2.35 | 1.86 | 1.61 | 1.46 | 1.47 |
| Liabilities / Assets | 0.75 | 0.73 | 0.70 | 0.58 | 0.45 | 0.57 | 0.46 | 0.38 | 0.32 | 0.32 |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | - | - | - | - | - | - | - | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 766d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | -12.5% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 65.4% | - | 34.7% | 42.4% | 58.3% | - | 16.4% | -20.8% | -9.4% | - |
| Net income growth (YoY) | 67.6% | - | 33.7% | 42.1% | 56.7% | - | 31.7% | -56.2% | 12.0% | - |
| EPS growth (YoY) | 77.8% | - | 67.6% | 46.9% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 29.0% | - | - | - | 12.2% | - | - | - | 0.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -51.5% | -41.4% | -54.9% | -69.2% | -54.9% | -64.6% | -52.8% | -16.9% | -20.4% | -29.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2019-12-31.
Product / service
$700.0K totalService$700.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SPECTRUM PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.